Impact of Magnesium Supplementation on Blood Pressure: An Umbrella Meta-Analysis of Randomized Controlled Trials

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2024-01-01 DOI:10.1016/j.curtheres.2024.100755

Abdullah M Alharran , Mooza M Alzayed , Parsa Jamilian , Kousalya Prabahar , Aminah Hassan Kamal , Muteb N Alotaibi , Omar E Elshaer , Mshal Alhatm , Mohd Diya Masmoum , Benjamin Hernández-Wolters , Raghad Sindi , Hamed Kord-Varkaneh , Ahmed Abu-Zaid

{"title":"Impact of Magnesium Supplementation on Blood Pressure: An Umbrella Meta-Analysis of Randomized Controlled Trials","authors":"Abdullah M Alharran , Mooza M Alzayed , Parsa Jamilian , Kousalya Prabahar , Aminah Hassan Kamal , Muteb N Alotaibi , Omar E Elshaer , Mshal Alhatm , Mohd Diya Masmoum , Benjamin Hernández-Wolters , Raghad Sindi , Hamed Kord-Varkaneh , Ahmed Abu-Zaid","doi":"10.1016/j.curtheres.2024.100755","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aim</h3><p>Conflicting results on the effect of magnesium supplementation on blood pressure have been published in previous meta-analyses; hence, we conducted this umbrella meta-analysis of RCTs to provide a more robust conclusion on its effects.</p></div><div><h3>Methods</h3><p>Four databases including PubMed, Scopus, EMBASE, and Web of Science were searched to find pertinent papers published on international scientific from inception up to July 15, 2024. We utilized STATA version 17.0 to carry out all statistical analyses (Stata Corporation, College Station, TX, US). The random effects model was used to calculate the overall effect size ES and CI.</p></div><div><h3>Findings</h3><p>Ten eligible review papers with 8610 participants studied the influence of magnesium on SBP and DBP. The pooling of their effect sizes resulted in a significant reduction of SBP (ES = -1.25 mmHg; 95% CI: -1.98, -0.51, <em>P</em> = 0.001) and DBP (ES = -1.40 mmHg; 95% CI: -2.04, -0.75, <em>P</em> = 0.000) by magnesium supplementation. In subgroup analysis, a significant reduction in SBP and DBP was observed in magnesium intervention with dosage ≥400 mg/day (ES for SBP = -6.38 mmHg; ES for DBP = -3.71mmHg), as well as in studies with a treatment duration of ≥12 weeks (ES for SBP = -0.42 mmHg; ES for DBP = -0.45 mmHg).</p></div><div><h3>Implications</h3><p>The findings of the present umbrella meta-analysis showed an overall decrease of SBP and DBP with magnesium supplementation, particularly at doses of ≥400 mg/day for ≥12 weeks.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100755"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000250/pdfft?md5=a8b8a2dc668f12e5bef20f98052ac230&pid=1-s2.0-S0011393X24000250-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X24000250","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aim

Conflicting results on the effect of magnesium supplementation on blood pressure have been published in previous meta-analyses; hence, we conducted this umbrella meta-analysis of RCTs to provide a more robust conclusion on its effects.

Methods

Four databases including PubMed, Scopus, EMBASE, and Web of Science were searched to find pertinent papers published on international scientific from inception up to July 15, 2024. We utilized STATA version 17.0 to carry out all statistical analyses (Stata Corporation, College Station, TX, US). The random effects model was used to calculate the overall effect size ES and CI.

Findings

Ten eligible review papers with 8610 participants studied the influence of magnesium on SBP and DBP. The pooling of their effect sizes resulted in a significant reduction of SBP (ES = -1.25 mmHg; 95% CI: -1.98, -0.51, P = 0.001) and DBP (ES = -1.40 mmHg; 95% CI: -2.04, -0.75, P = 0.000) by magnesium supplementation. In subgroup analysis, a significant reduction in SBP and DBP was observed in magnesium intervention with dosage ≥400 mg/day (ES for SBP = -6.38 mmHg; ES for DBP = -3.71mmHg), as well as in studies with a treatment duration of ≥12 weeks (ES for SBP = -0.42 mmHg; ES for DBP = -0.45 mmHg).

Implications

The findings of the present umbrella meta-analysis showed an overall decrease of SBP and DBP with magnesium supplementation, particularly at doses of ≥400 mg/day for ≥12 weeks.

查看原文本刊更多论文

补充镁对血压的影响：随机对照试验的总括性元分析

背景和目的在以往的荟萃分析中，关于补充镁对血压的影响曾出现过相互矛盾的结果；因此，我们对 RCTs 进行了这项总括荟萃分析，以便为其效果提供更可靠的结论。方法检索了 PubMed、Scopus、EMBASE 和 Web of Science 等四个数据库，以查找从开始到 2024 年 7 月 15 日期间发表的国际科学论文。我们使用 STATA 17.0 版进行了所有统计分析（Stata Corporation，College Station，Texas，US）。研究结果10篇符合条件的综述性论文共有8610名参与者，研究了镁对SBP和DBP的影响。汇总这些论文的效应大小后发现，补充镁可显著降低 SBP（ES = -1.25 mmHg；95% CI：-1.98, -0.51，P = 0.001）和 DBP（ES = -1.40 mmHg；95% CI：-2.04, -0.75，P = 0.000）。在亚组分析中，观察到剂量≥400 毫克/天的镁干预可显著降低 SBP 和 DBP（SBP 的 ES = -6.38 mmHg；DBP 的 ES = -3.71mmHg），治疗持续时间≥12 周的研究也是如此（SBP 的 ES = -0.本总括荟萃分析的结果表明，补充镁后 SBP 和 DBP 总体下降，尤其是剂量≥400 毫克/天且持续时间≥12 周时。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.